These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36856571)

  • 1. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
    Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
    Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
    [No Abstract]   [Full Text] [Related]  

  • 2. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
    Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
    Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs.
    Tookes HE; Bartholomew TS; Suarez E; Ekowo E; Ginoza M; Forrest DW; Serota DP; Rodriguez A; Kolber MA; Feaster DJ; Mooss A; Boyd D; Sternberg C; Metsch LR
    Drug Alcohol Depend; 2021 Dec; 229(Pt A):109124. PubMed ID: 34781096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.
    Bartholomew TS; Andraka-Cristou B; Totaram RK; Harris S; Doblecki-Lewis S; Ostrer L; Serota DP; Forrest DW; Chueng TA; Suarez E; Tookes HE
    Harm Reduct J; 2022 Dec; 19(1):133. PubMed ID: 36463183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving access to HIV care among people who inject drugs through tele-harm reduction: a qualitative analysis of perceived discrimination and stigma.
    Scaramutti C; Hervera B; Rivera Y; Chueng TA; Forrest DW; Suarez E; Serota DP; Alkamli H; Ciraldo K; Bartholomew TS; Tookes HE
    Harm Reduct J; 2024 Feb; 21(1):50. PubMed ID: 38396017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network centrality and HIV prevention service use among people who inject drugs: Findings from a sociometric network cohort in New Delhi, India.
    Prata Menezes N; Mehta SH; Wesolowski A; Clipman SJ; Srikrishnan AK; Kumar MS; Zook KJC; Lucas GM; Latkin C; Solomon SS
    Addiction; 2024 Mar; 119(3):570-581. PubMed ID: 37967827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injection network drivers of HIV prevention service utilization among people who inject drugs: results of a community-based sociometric network cohort in New Delhi, India.
    Prata Menezes NS; Mehta SH; Wesolowski A; Clipman SJ; Srikrishnan AK; Kumar MS; Zook KJC; Lucas GM; Latkin C; Solomon SS
    J Int AIDS Soc; 2024 Apr; 27(4):e26241. PubMed ID: 38632848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts.
    Hassan R; Roland KB; Hernandez B; Goldman L; Evans KN; Gaul Z; Agnew-Brune C; Buchacz K; Fukuda HD
    J Subst Abuse Treat; 2022 Jul; 138():108722. PubMed ID: 35067399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities.
    Handanagic S; Broz D; Finlayson T; Kanny D; Wejnert C;
    Drug Alcohol Depend; 2024 Apr; 257():111251. PubMed ID: 38457965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India.
    Ganapathi L; McFall AM; Greco KF; Srikrishnan AK; Kumar MS; Mayer KH; O'Cleirigh C; Mehta SH; Lucas GM; Solomon SS
    Drug Alcohol Depend; 2023 May; 246():109839. PubMed ID: 37031487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state.
    Thakarar K; Kohut M; Hutchinson R; Bell R; Loeb HE; Burris D; Fairfield KM
    Harm Reduct J; 2022 Jul; 19(1):80. PubMed ID: 35869523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study.
    Shelby T; Zhou X; Barber D; Altice F
    J Med Internet Res; 2021 Jul; 23(7):e25428. PubMed ID: 34259640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
    Carter J; Li Z; Chen H; Greiner M; Bush C; Bhattacharya D; Poley S; Sachdeva N; Crowder JC; Feigal J
    Addict Sci Clin Pract; 2022 Nov; 17(1):60. PubMed ID: 36335381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.